About Us

GRANITE BIO is a private biotechnology company located in Basel (Switzerland). GRANITE BIO is supported by top‑tier investors with ~$100M raised to date. Based on fundamental research conducted over the last two decades, GRANITE BIO’s is pursuing a differentiated approach to transform inflammatory, autoimmune, and fibrotic conditions. Both our programs are first‑in‑class monoclonal antibodies for large market opportunities in Immunology and Inflammation. GRT‑001, the lead asset, depletes inflammatory monocytes. It has just completed a Phase 1a trial in healthy volunteers and has shown favorable safety and pharmacodynamic effect. The Phase 1b trial in patients with Ulcerative Colitis has just started. GRT‑002 is an IL‑3 neutralizing antibody that is thought to play an important role in type II inflammation. Our company fosters an open, inter‑disciplinary, diverse, international and creative working environment. We enable work‑from‑home options according to our in...